Giant Biogene's stock price surged 5.49% during intraday trading on Monday, marking a significant upward movement for the company's shares.
The rally follows the market's digestion of the company's recently released annual financial results. According to the earnings report, Giant Biogene posted full-year revenue of RMB 5.519 billion, representing a 0.4% year-over-year decline, while attributable net profit decreased by 7.2% to RMB 1.915 billion.
This marked the first instance since the company's listing that both revenue and net profit failed to sustain double-digit growth. However, the actual decline was relatively mild compared to market fears, and absolute profit levels remained substantial. With the stock having already experienced a significant valuation pullback prior to the results announcement, today's price movement reflects a recovery in investor sentiment as the reported figures proved less severe than anticipated.
Comments